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Université Paris Diderot and INSERM U773, Clichy-la-Garenne, FranceSummary IntroductionTo survey the burden of liver disease in Europe and its causes 260
epidemiological studies published in the last ﬁve years were
reviewed.
The incidence and prevalence of cirrhosis and primary liver
cancer are key to understand the burden of liver disease. They
represent the end-stage of liver pathology and thus are indicative
of the associated mortality. About 0.1% of Hungarian males will
die of cirrhosis every year compared with 0.001% of Greek
females. WHO estimate that liver cancer is responsible for around
47,000 deaths per year in the EU.
Harmful alcohol consumption, viral hepatitis B and C and
metabolic syndromes related to overweight and obesity are
the leading causes of cirrhosis and primary liver cancer in
Europe.
Chronic hepatitis B affects 0.5–0.7% of the European popu-
lation. In the last decade the prevalence of chronic hepatitis
C was 0.13–3.26%. It is of great concern that about 90%
of people in Europe infected by viral hepatitis are unaware
of their status. Available data suggest the prevalence rate of
NAFLD is 2–44% in the general European population (includ-
ing obese children) and 42.6–69.5% in people with type 2
diabetes.
Each of these four major causes of liver disease is amenable to
prevention and treatment, reducing the burden of liver disease in
Europe and saving lives. Further surveys are urgently needed to
implement cost-effective prevention programmes and novel
treatments to tackle this problem.
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coise.roudot-thoraval@hmn.aphp.fr (F. Roudot-Thoraval).In the past 30 years there has been major progress in the knowl-
edge and management of liver disease yet approximately 29 mil-
lion persons in the European Union still suffer from a chronic
liver condition. Difﬁculties in accessing data from individual
countries hinder comprehensive evaluation of the burden of liver
disease in Europe and comparison with other diseases. Moreover,
very few reviews have studied both chronic liver conditions, such
as cirrhosis and cancer, and their major causes, such as viral hep-
atitis, alcohol intake, and metabolic syndrome. It is likely that the
causes of chronic liver diseases differ from country to country,
but no reliable data exist about this. A large systematic review
of all epidemiological data available for European countries has
hitherto not been undertaken.
Here we review evidence of the burden and causes of liver dis-
ease in Europe, drawing on a survey of all epidemiological data
published in the last ﬁve years.Methods
MEDLINE, EMBASE, and the Cochrane Library were searched for
relevant articles using the following medical subject headings
(MeSH) terms: ‘liver’ and [‘disease’ or ‘epidemiology’]. The search
encompassed articles published in the last ﬁve years in any Euro-
pean language. Studies were included if: (1) they presented epi-
demiological data; (2) they included patients who lived in the
European Union (EU27) or Norway (but not necessarily exclu-
sively so); (3) they were published or accepted for publication
as full-length articles. Studies were excluded if: (1) they esti-
mated prevalence or incidence from data collected before 1995;
(2) they studied very speciﬁc populations; (3) they were pub-
lished only in abstract form so that the methodological quality
could not be assessed. When the results of a single study were
reported in more than one publication, only the most recent
and complete data were included in the systematic review.
A manual search of references cited in retrieved articles was
also conducted to identify studies not found in the database
search. Data presented in World Health Organization (WHO)
reports, in European Centre for Disease Prevention and Control
(ECDC) reports and on EUROHEP.NET were also included.13 vol. 58 j 593–608
Special Review
All available data on liver disease incidence and prevalence
and on associated mortality and trends were extracted from the
reviewed articles. Most mortality statistics were derived from
ofﬁcial causes of death recorded on death certiﬁcates. Of 4256
reviewed studies, 260 met the inclusion criteria.
The European Liver Transplant Registry (ELTR) was used to
describe the epidemiologyof liver transplantation inEurope as it rep-
resentsmore than95%of all ofﬁcial published European data (Fig. 5).
Geographical factors necessitate caution in the interpretation of
parts of this review for two reasons: (1) inter-country variation in
death-reporting processes; therefore cautionmust be exercisedwhen
makingcomparisonsbetweencountries; (2) thedeﬁnitionof theEuro-
pean zone varies according to the source, so caremust be takenwhen
assessing data reported at the European level. According to WHO,
European countries include all eastern and central European countries
as well as the Russian Federation. By contrast, data given for the
EU27 refer only to countries that belong to the European Union.
Key Points
• A review of 260 epidemiological studies published in
the last five years
• Liver cirrhosis is responsible for around 170,000 
deaths in Europe each year, with large inter-country
variation
• Liver cancer is responsible for around 47,000 deaths
per year in the EU
• More than 5500 liver transplants are performed in
Europe per year
• In some European countries the mortality rate from
alcohol-related liver disease is as high as 47 per 
100,000 inhabitants
• 0.5-0.7% of the European population is affected by
chronic hepatitis B
• The overall prevalence of hepatitis C in Europe is
estimated at 0.13-3.26%
• The prevalence of non-alcoholic fatty liver disease
(NAFLD) is 2-44% in the general European population
(including obese children) and 42.6-69.5% in people
with type 2 diabetes. There is the potential for this
condition to become a serious problem in light of the
obesity epidemic
• All of the major causes of liver disease are amenable
to prevention and treatment
• Strategies are urgently required to reduce the burden
of liver disease in EuropeCirrhosis
WHO reports that liver cirrhosis accounts for 1.8% of all deaths in
Europe (170,000 deaths per year) with the highest rates observed
in south-eastern and north-eastern Europe [1,2] (Fig. 1). However,
in somewestern European countries (e.g. UK and Ireland) liver cir-
rhosis-associated mortality has increased over the last ten years.594 Journal of Hepatology 201Alcohol is the strongest risk factor for liver cirrhosis [3,4] and
cirrhosis mortality is a valid indicator for tracing the health con-
sequences of alcohol abuse. However, infections by the hepatitis
B and C viruses (HBV and HCV) are also important determinants
of cirrhosis, and their possible contribution to temporal trends
should be taken into account. A study based on the WHO mortal-
ity database (http://data.euro.who.int) reports radical increases
in liver cirrhosis mortalities from the 1970s within a group of
several south-eastern European countries. For example, in Hun-
gary from the mid-1970s to the mid-1990s, cirrhosis mortality
rates increased from 20 to 148 per 100,000 males (the highest
level ever registered in any European country) and from about
8 to 48 per 100,000 females [2]. By 2002 these rates had slightly
declined to 103 per 100,000 males and 32 per 100,000 females
[2]. Dramatic changes were also observed in north-eastern Euro-
pean countries (e.g. Estonia, Latvia, Lithuania and Poland).
Appreciabledeclines in cirrhosismortalitywereobserved inMed-
iterranean countries (e.g. France, Italy, Spain, Portugal and Greece)
that historically had the highest cirrhosis mortality levels in both
sexes. HBV vaccination, reduced alcohol consumption and reduction
of HCV transmission have probably contributed to this decrease. Per-
haps bucking this trend is a French study that found 0.3% of screened
males (aged >40 years) had liver cirrhosis; however, the subjects
were seen within a free screening programme and therefore were
potentially at high risk of liver ﬁbrosis [5]. The associated causes of
liver disease in this study were alcoholic and NAFLD (66%), NAFLD
only (13%), alcohol (9%), HCV (6%), and other causal factors (6%) [5].
Factors independently associated with ﬁbrosis were age, male gen-
der, waist circumference, presence of HCV antibody and alcohol con-
sumption [5]. These results suggest that alcohol andNAFLD are two
causal factorswith the potential to keep levels of liver cirrhosis rel-
atively high in western European countries.
A summary of cirrhosis rates in four northern European coun-
tries is presented in Table 1.
Primary liver cancer
Hepatocellular carcinoma (HCC), accounts for 70–90% of primary
liver cancers (PLC). The management of HCC is complicated by
the presence of liver cirrhosis in more than 80% of patients.
Over half a million new cases of HCC are diagnosed each year
worldwide [6–8]. In recent years decreasing incidence has been
reported in some high incidence countries, while signiﬁcant increases
have been reported in several low incidence countries [6,9,10]. The
GLOBOCANproject (http://globocan.iarc.fr) provides estimates of liver
cancer incidence rates foreachEU27country. In theEU27 in2008, liver
cancer incidence was 10.6 and 3.6 per 100,000 persons for men and
women, respectively [11]. For men, the highest incidence was in Italy
and the lowest was in the Netherlands [11]. As expected, estimated
mortality rates were very close to incidence rates, indeed the two
measures were exactly the same for the EU27 overall (Fig. 2) [11].
The few European studies that have investigated the incidence
of PLC were all based on local or national registries (Table 2).
Liver cancer is responsible for 46,801 deaths per annum in Eur-
ope, according to the WHO mortality database. Unlike other can-
cers, the mortality rate is very close to the incidence rate because
of the very low associated survival rate.
Liver transplantation
More than 5500 liver transplants (LTs) are currently performed in
Europe per year [12] (Fig. 3). After rapid growth in the 1980s and3 vol. 58 j 593–608
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Fig. 1. Age-standardized death rates per 100,000 population from liver cirrhosis in European countries, males and females aged 20–64; WHO mortality database
2000–2002 [2].
Table 1. European studies assessing the prevalence or incidence of liver cirrhosis.
Country Author, [Ref.] Study years and population Diagnosis Prevalence or incidence 
rates (95% CI)
Trends in prevalence or 
incidence rates
Denmark Jepsen et al., 
[115]
1988-2005; alcoholic cirrhosis: 
a nationwide population-
based, hospital registry study
Histology In 2001-2005, the alcoholic 
cirrhosis incidence rates 
were 22.5 (25.7-17.4) 
and 11.8 (11.2-12.4) per 
100,000 per year for men 
and women, respectively, 
and the prevalence rates 
were 132.6 (130.7-134.5) 
and 70.1 (68.8-71.5) per 
100,000
The alcoholic cirrhosis 
prevalence and incidence 
rates for men and women 
of any age did not change 
2005
France Poynard et al.,
[5]
2006-2008; 7463 consecutive 
subjects aged 40 years or 
older, seen for a free voluntary 
screening program in two 
French Social Security health 
examination centres, 95% 
male
Histology The estimated prevalence 
1.7%) and of cirrhosis was 
0.3% (0.2-0.5%)
Sweden Gunnarsdottir et 
al., [116]
1994-2003; all patients 
diagnosed with liver cirrho-
sis in Gothenburg (600,000 
inhabitants) 
Histology The mean annual inci-
dence rate per 100,000 
inhabitants in Sweden was 
15.3 (± 2.4)
The incidence rate and 
the proportion of alcohol 
aetiology were fairly con-
stant over the study period
UK Fleming et al., 
[117]
1992-2001; the UK General 
Practice Research Database 
(GPRD), persons aged 25 and 
over, 58% male
Any diagnostic or 
therapeutic code 
for cirrhosis, 
oesophageal 
varices or portal 
hypertension
Crude incidence was 14.55 
per 100,000 person years. 
Prevalence of cirrhosis 
was an estimated 76.3 per 
100,000 population aged 
over 25 in mid-2001
The cirrhosis incidence 
increased from 12.05 to 
16.99 per 100,000 person 
years from 1992 to 2001
UK Liu et al., [118] 1996-2005; the Million Women 
Study (an on-going prospec-
tive study of 1.3 million United 
Kingdom women aged 50 and 
over
ICD-10 diagnosis 
code K70, K73, or 
K74
After a mean follow-up of 
6.1 years (1996-2005), 
incidence rate of cirrhosis  
was 26 per 100,000 per  
person-years in women
 
significantly from 1996 to
of fibrosis was 1.3% (1.1-
(See above-mentioned references for further information.)
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Fig. 2. (A) Estimated age-standardized incidence rates of liver cancer per 100,000 in 2008; WHO, GLOBOCAN, 2008. (B) Estimated age-standardized mortality rates
per 100,000 for liver cancer in 2008; WHO, GLOBOCAN, 2008.
Special Review1990s the annual number of LTs has stopped growing in the last
10 years. Donor shortage currently represents the most impor-
tant limiting factor for LT [13,14]. Furthermore, alternatives to
standard cadaveric LT, such as split (one liver divided for two
recipients) or living related (a portion of a healthy person’s liver
is used) LT’s now account for 11% of all procedures [15,16].
Of particular note is the fact that LT outcomes have improved
signiﬁcantly over time. Currently the 1-year survival rate is
reported to be 83% (all indications considered). This improve-
ment is probably due to greater technical expertise, better selec-
tion of patients, and improved post-LT management of
complications and immunosuppressive therapy.
Alcohol and liver disease
Europe is the heaviest drinking region in the world in terms of
the prevalence of alcohol consumption [17]. Over 20% of the596 Journal of Hepatology 201European population agedP15 reported heavy episodic drinking
(deﬁned as ﬁve or more drinks on one occasion, or 50 g alcohol)
at least once a week [17].
Alcohol is the main cause of liver disease, including liver cir-
rhosis. Indeed, the cirrhosis mortality rate is a good indicator of
alcohol-related mortality [2]. In turn, cirrhosis can lead to hepa-
tocellular carcinoma. In France, 69% of PLC cases are caused by
excessive alcohol consumption, making it the main risk factor,
although viral aetiology is growing [18]. Alcohol-related cirrhosis
has increased in Estonia [19] and in Denmark [20] in the last dec-
ade corresponding with increases in alcohol consumption in the
1990s in those countries.
Standardized mortality rates for alcohol-related liver diseases
among men and women during 2000–2005 in 24 European coun-
tries show a signiﬁcant impact of chronic alcohol consumption on
health in Europe (Fig. 4). The ﬁgures vary greatly between coun-
tries, ranging from 3 to 47 per 100,000 men in Latvia and3 vol. 58 j 593–608
Table 2. European studies assessing incidence of primary liver cancer.
Country Author, [Ref.] Study year(s) and 
population
Diagnosis Standardized incidence rates 
per 100,000 person-years
Trends in incidence rates
EU27 Ferlay et al., 
[11],
GLOBOCAN
2008; local cancer 
registries
Histology or clinical 10.6 in men, 3.6 in women
Denmark Erichsen et al., 
[119]
1985-2004; the three 
Danish counties of North 
Jutland, Aarhus and Viborg
Histology or clinical 5.9 (95% CI 5.4-6.3) in men, 
3.7 (95% CI 3.4-4.0) in 
women in 1985-2003
Increased from 3.2 (95% 
CI 2.2-4.2) to 5.0 (95% 
CI 3.8-6.2) from 1985 to 
2003
France Borie et al., [18] 1997-1998; 9 regional 
French registries 
Histology or clinical 9.5 in men, 1.7 in women
France Caumes et al., 
[120]
2002-2003; the Finistère 
cancer registry
Histology or clinical 13.8 in men, 0.8 in women
France Binder-Foucard 
et al., [121]
1990-1999; the cancer 
registry of Bas-Rhin 
Histology or clinical 11.7 in men, 1.5 in women No incidence trend for 
men or women (p = 0.75)
Italy Dal Maso et al., 
[122]
1998-2002; 20 Italian 
cancer registries 
Histology or clinical 21.1 in men, 6.0 in women. 
In Naples, the world-stand-
ardized incidence rates for 
persons aged 0-79 were 29.5 
and 8.3 per 100,000 in men 
and women, respectively, 
approaching those found in 
highest risk areas of Asia.
The change in annual 
incidence rate between 
1988 and 2002 was 0.8% 
in men (95% CI 0.5-2.1%) 
and 1.1% in women (95% 
CI 0.2-2.1%).
and imaging findings
and imaging findings
and imaging findings
and imaging findings
and imaging findings
and imaging findings
(See above-mentioned references for further information.)
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Fig. 3. Number of liver transplantations in European countries, May 1968 to
December 2009; ELTR [12].
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Journal of Hepatology 201Hungary, respectively. These data should be interpreted cau-
tiously because of inter-country variation in the way mortality
is declared and how alcohol-related diseases are reported in
death certiﬁcates. Countries such as Norway and Sweden demon-
strate the mortality reductions that can be achieved with the
implementation of appropriate alcohol policies.
Data on the acute consequences of alcohol is scarce. From
1999 to 2008, the annual incidence rate of alcoholic hepatitis in
the Danish population rose from 37 to 46 and from 24 to 34
per 100,000 for men and women, respectively. The 5-year mortal-
ity was 47% without cirrhosis, 69% with cirrhosis and 56% overall
[21].
Alcohol consumption in Europe decreased during the 1990s,
but increased and stabilized at a higher level between 2004 and
2006, with huge variations among European countries [17]. The
burden of liver disease attributable to the harmful use of alcohol
is signiﬁcant compared to other aetiologies. Moreover, the bur-
den of general health, social and economic issues related to alco-
hol consumption is substantial.
Hepatitis A
In most European countries recent decades have seen a dramatic
drop in the incidence of hepatitis A and a shift in the age-speciﬁc
seroprevalence rates. This trend is largely due to improvements
in hygiene and sanitation coupled with economic and social
advancement (Table 3). As a consequence, a smaller fraction of
the population is immune, especially early in life when hepatitis
A virus (HAV) infection is mainly asymptomatic. The yearly inci-
dence rate of hepatitis A in Europe today is between 0.55 and 1.5
cases per 100,000 inhabitants (Table 3), but there is signiﬁcant3 vol. 58 j 593–608 597
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Special Reviewinter-country variation. Hospitalization rates for HAV infection
range from 0.2 per 100,000 inhabitants in the Netherlands to
94 per 100,000 in Romania (Fig. 5).
Declining HAV incidence and seroprevalence have delayed the
age at which individuals become infected until adulthood when
the likelihood of developing the symptomatic illness is consider-
ably higher. Because of the greater disease burden of late HAV
infections several countries have considered systematic vaccina-
tion programmes, which can reduce incidence, outbreaks, mortal-
ity rates, and hospitalization [22]. One strategy is to combine
HAV and hepatitis B virus (HBV) vaccination. Cost effectiveness
analyses performed in Ireland showed vaccination to be the strat-
egy of choice where HAV immunity is 45% or less [23] (Table 4).
Reduced population protection leads to more symptomatic
cases and to outbreaks; therefore HAV remains a threat to Euro-598 Journal of Hepatology 201pean public health, despite declining incidence. Epidemics were
responsible for a 10-fold increase in the incidence rate in the
Czech Republic in 2008 [24,25] and an incidence rate of 124
per 100,000 inhabitants in Latvia in 2008 [26]. Finnish epidemics
in 1994–1995 and 2002–2003 began with intravenous drug users
before spreading to the rest of the population [27]. The economic
impact of a HAV outbreak can be substantial, ranging from USD
3824 to USD 200,480 per case [28].
Hepatitis B
The hepatitis B virus (HBV) has sometimes been called ‘the silent
killer’ because infected adults often remain undiagnosed and thus
untreated until it is too late. Throughout Europe, an average of
23% of patients knew of hepatitis B at the time of their diagnosis3 vol. 58 j 593–608
Table 3. Incidence rates of HAV infection in Europe.
Country Author, [Ref.] Study year(s) and 
population
Incidence rates 
per 100,000
Trends in incidence rates
Czech
Republic
Fabianova et al., 
[25]
2003-2007; general 
population
Mandatory case declaration 1.48
Italy Tosti et al., [123] 2006; general population Epidemiological 
surveillance system
1.4 Decreased from 4.0 in 1991.
Netherlands Suijkerbuijk et al., 
[124]
2005; general population Mandatory case declaration 1.3 Decreased from 6.5 in 1995
Poland Baumann et al., 
[125]
2007; general population Mandatory case declaration 0.09 A decrease of 31% compared 
to 2006 (part of a downward 
trend since 1997)
Poland Baumann et al., 
[126]
2008; general population Mandatory case declaration 0.55 Increased from 0.09 in 2007
Spain Arteaga et al., 
[127, 128]
2008; general population Hospitalization 1.36 Decreased from 1.87 in 2005
Case identification
(See above-mentioned references for further information.)
Table 4. Prevalence rates of HAV infection in Europe.
Country Author, [Ref.] Study year(s) and 
population
Diagnostic method Prevalence rates 
(95% CI)
Trends in prevalence rates
Belgium Quoilion et al., 
[129]
2007; general population Oral (saliva) testing for 
antibodies
20.2% 
(19.43-21.08) 
weighted for age 
Finland Broman et al., 
[27]
1990-2007; patient 
sample
Oral (saliva) testing for 
antibodies
30-45%*
Greece Kyrka et al., 
[130]
2008; unvaccinated 
children 0-14 years old
Oral (saliva) testing for 
antibodies
17.1% 
Italy D’Amelio et al., 
[131]
2005; military recruits Oral (saliva) testing for 
antibodies
5.3% Decreased from 66.3% in 
1981 to 29.4% in 1990
(See above-mentioned references for further information.)
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Fig. 6. Incidence rates of hepatitis B in EU27 countries in 2005; ECDC 2007. NB: there is no of standardized deﬁnition of new HBV cases; sometimes reactivations are
included.
Table 5. Age-speciﬁc HBV seroprevalence in European countries [132].
Country % anti-HBC % HBsAg
Belgium 1.3 0.7
Czech Republic 2.5 0.3
Germany 6.0 -
Italy 5.6 0.6
Luxembourg 2.9 -
Romania 20.5 5.6
Slovakia 10.5 0.6
Finland 2.7 0.2
Ireland 1.7 0.1
Netherlands 1.7 0.1
France* 7.0 0.65
⁄Data added from Institut de Veille Sanitaire, 2004 [133].
Special Reviewand only 27% knew they were at risk of contracting it [29]. In
France 18% of identiﬁed patients were detected by standard test-
ing during pregnancy [30].
The yearly incidence of new cases of HBV shows large varia-
tion from 0.2 to 11.2 cases per 100,000 inhabitants in France
and Iceland, respectively (Fig. 6).
Estimates for the prevalence of chronic HBV infections, based
on hepatitis B surface antigen (HBsAg) identiﬁcation in sera col-
lected from the general population, range from 0.1–0.7%, with
the exception of Romania (5.6%) and Greece (3.4%) (Tables 5
and 7).
The disease burden of chronic hepatitis B in Europe is signiﬁ-
cant. Cirrhosis occurs in 20–30% of chronically infected patients
[30,31] with about 25% at risk of developing HCC, thus HBV is
responsible for 10–15% of hepatocellular carcinoma [32]. HBV
infected patients also have an excess risk of all-cause mortality
and liver-related mortality [33], about 46% of which is explained
by liver cancer. HBV infection is responsible for a mortality rate of
2.7 and 2.5 persons per 100,000 inhabitants per year in Spain and
France, respectively [34,35].600 Journal of Hepatology 201Data suggest there has been a reduction in the yearly inci-
dence of HBV, accompanied by a decline in prevalence related
to vaccination campaigns (Tables 6 and 7) [36,37]. However, a
lack of reliable epidemiological data on HBV is one of the biggest
barriers to the development of policies for its management. For
example, surveillance data collected by the ECDC must be inter-
preted with caution because of the absence of a standardized def-
inition of HBV infection.
Despite vaccination and decreased incidence, HBV infection
remains a public health issue, not only because of its silent nat-
ure, but also because of its associated complications.
Hepatitis C
In Europe, a signiﬁcant number of persons acquired hepatitis C
virus (HCV) in the 1970s and 1980s before the virus was identi-
ﬁed and a diagnostic test was available. Since then, the transmis-
sion of infection has been greatly reduced and it is now mainly
concentrated in intravenous drug users. However the disease
has a prolonged time-course – individuals developing cirrhosis
within 20 years [38] – so the disease burden of HCV in Europe
is at its peak only now.
Reliable epidemiological data on HCV in Europe is lacking
[39]. The annual average incidence rate is estimated at 6.19 per
100,000 inhabitants (95% CI 4.90–7.48) [39]. Overall prevalence
in Europe, estimated from serum antibodies, varies between
0.13% and 3.26% (Table 8), which aligns with the 0.003–4.5%
prevalence rate reported by WHO for the wider European region
[39]. In intravenous drug users prevalence rates range from up to
50% in Cyprus [40], 59.8% (95% CI 50.7–68.3) in France [41], 75%
for those admitted for opiate detoxiﬁcation in Germany and
83.2% in Italy [42,43].
Up to 85% of infected patients develop a chronic infection,
with 10–20% progressing to cirrhosis [44]. About 7% of cirrhosis
patients develop HCC [45] and HCV is an important risk factor
for this cancer [32]. HCV is also the main indication for virus-
related liver transplantation. Patients diagnosed with hepatitis
C show increased morbidity, higher hospital admission rates3 vol. 58 j 593–608
Table 6. HBV incidence in Europe.
Country Author, [Ref.] Study year and population Incidence rates 
per 100,000
Trends in incidence rates
Poland Czarkowski et 
al., [134, 135]
2006; general population Mandatory declaration 4.4 Stable since 2005 when the 
rate was 4.5
Romania Pitigoi et al., 
[136]
2004; general population Mandatory declaration 8.5 Decreased from 43 in 1989
Case identification
(See above-mentioned references for further information.)
Table 7. Seroprevalence of chronically HBV-infected patients in Europe.
Country Author, [Ref.] Study year and population Diagnostic method Seroprevalence Trends in seroprevalence
Belgium Quoilin et al., 
[129]
2006; general population HBs antigen testing in 
saliva
0.66% 
France Meffre et al., 
[137]
2004; general population HBs antigen testing in 
serum
0.65%
Greece Zacharakis et 
al., [37]
2006; general population HBs antigen testing in 
serum
3.4% Decreased from 5.4% in 1994
Greece Papaevangelou 
et al., [138]
1998; children HBs antigen testing in 
serum
0.6%
Italy Fabris et al., 
[139]
2007; general population 
in northern Italy
HBs antigen testing in 
serum
1%
Netherlands Baaten et al., 
[140]
2004; general population 
in Amsterdam
HBs antigen testing in 
serum
0.4%
Romania Voiculescu et al., 
[141]
2009; general population 
SE Romania
HBs antigen testing in 
serum
5.6%
Spain Salleras et al., 
[142]
2002; general population 
in Catalonia
HBs antigen testing in 
serum
0.7% (0.4-1%) Decreased from 1.5% in 1989
(See above-mentioned references for further information.)
JOURNAL OF HEPATOLOGY[46] and mortality rates three times higher than that of the gen-
eral population, due to both drug use and liver disease [47]. In
France there are 2.5 HCV-associated deaths per 100,000 inhabit-
ants (95% with cirrhosis and 33% with HCC at death) [35]. In
Spain, the mortality rate due to HCV infection is 11.25 per
100,000 inhabitants [34]. Cost analysis, including the cost of com-
plications, shows that the median lifetime cost for treating one
patient with dual therapy (pegylated interferon and ribavirin) is
EUR 7517 to EUR 21,229, depending on the virus genotype [48].
In cost effectiveness analyses of new protease inhibitors for treat-
ing chronic hepatitis C universal triple therapy costs an additional
USD 70,100 per QALY (mild ﬁbrosis) and USD 36,300 per QALY
(advanced ﬁbrosis) compared with standard pegylated interferon
plus ribavirin therapy [49].
Models suggest that HCV-related morbidity will rapidly
increase in the short term. In the UK, HCV-related cirrhosis and
death from HCC are projected to increase dramatically in the next
decade, reﬂecting the increased incidence of HCV infection in the
early 1980’s [50]. Modelling also suggests that treatment with
pegylated interferon and additional effects of triple therapy with
a protease inhibitor could reduce HCV genotype 1-related cumu-
lative incidence by 17.7% and mortality by 9.7% between 2012
and 2021 [51].
Although HCV transmission has been greatly reduced and pre-
vention strategies have been effective [52], patients now chroni-Journal of Hepatology 201cally infected with HCV will represent a heavy disease burden in
the coming years.
Hepatitis D
Hepatitis delta virus (HDV) can only infect an individual co-
infected or super-infected by HBV [53]. Most patients with
HBV/HDV co-infection develop chronic infection and have more
severe liver disease [54,55], more rapid progression to cirrhosis
[56,57] and increased hepatic decompensation and death [58]
compared with patients who have chronic HBV infection alone.
The highest prevalence is seen in central Africa, the Horn of
Africa, the Amazon Basin, eastern and Mediterranean Europe,
the Middle East, and parts of Asia [59]. Most cases recorded in
other European countries are found in populations originating
from endemic regions. Limited data are available for basing an
estimate of HDV prevalence in European countries.
Among 16,597 HIV patients enrolled in EuroSIDA, 61 of 422
(14.5%) HBsAg-positive carriers were anti-HDV positive. HDV
predominated in intravenous drug users and in southern and/or
eastern Europe. Serum HDV-RNA was detectable in 87% of anti-
HDV-positive patients [60].
In Switzerland the prevalence of HDV infection in 1,699
patients with chronic hepatitis B was 5.9% [61]. In a German
study hepatitis D prevalence increased from 4.1% to 6.2% among3 vol. 58 j 593–608 601
Table 8. HCV prevalence in Europe.
Country Author Study year and population Prevalence Trends in prevalence
Belgium Quoilin et al., 
[129]
2007; general population Anti-HCV testing in saliva 0.12%
France Meffre et al.,  
[137]
2004; general population Anti-HCV testing in serum 0.65%
France Delarocque-
Astagneau et al., 
[52]
2004; adults aged 20-59  Anti-HCV testing in serum 0.71% Decreased from 1.05% in 
1994
Italy Cozzolongo et 
al., [143]
2007; southern Italian 
town
Anti-HCV testing in serum 2.6%
Italy Fabris et al., 
[139]
2008; northern Italy Anti-HCV testing in serum 2.6%
Netherlands Baaten [140] 2004; general population Anti-HCV testing in serum 0.6%
Romania Gheorghe [144] 2008; general population Anti-HCV testing in serum 3.23%
Case identification
(See above-mentioned references for further information.)
Table 9. European studies assessing the prevalence of NAFLD.
Country Author, [Ref.] Study year(s) and population Prevalence 
(of NAFLD unless otherwise stated)
14 EU countries Gastaldelli et 
al., [145]
2002-2004; 1400 apparently healthy 
subjects between 30 and 60 yr, 44% 
male
Fatty Liver Index* 33%
Germany Imhof et al., 
[83]
2002; 378 children and adolescents 
aged 12-20 yr, 49% male
Ultrasonography 
and liver enzymes
2% overall, 36% in obese male children
Germany Haring et al., 
[79]
2007; 4160 subjects aged 20-79 yr Ultrasonography 30.4%
Greece Zois et al., 
[81]
2006-2008; post-mortem material from 
498 patients aged 3-94 yr, 68% male
Histology 31% NAFLD and 40% NASH 
Italy Bedogni et 
al., [77]
2001-2002; 659 subjects aged 18-75 
yr, 58% male
Ultrasonography 26%
Italy Caserta et 
al., [82]
2007-2008; 676 adolescents aged 11-
13 yr, 49.5% male
Ultrasonography 12.5% (95% CI 10.0-15.3)
Italy Sartorio et 
al., [84]
2006; 268 obese children aged 6-20 
yr, 44% male
Ultrasonography 44%
Italy Targher et 
al., [85]
2005-2006; 2839 type 2 diabetic out-
patients aged 40-86 yr, 55% male
Ultrasonography 69.5% (95% CI 68.5-70.5)
Romania Radu et al., 
[80]
2006-2007; 3005 inpatients, mean age 
54 yr, 44% male
Ultrasonography 20%
Spain Caballeria et 
al., [146]
2007-2008; 773 individuals aged 15-85 
yr, 42% male
Ultrasonography 25.8% overall, 33.4% in men and 20.3% 
in women 
UK Williamson et 
al., [86]
2006-2007; 939 type 2 diabetic 
patients aged 60-74 yr, 52% male
Ultrasonography 46.2% 
Case identification
⁄Fatty Liver Index is based on BMI, waist circumference, triglycerides, and GGT. (See above-mentioned references for further information.)
Special ReviewHBsAg carriers during the two decades, 1989 to 2008 (p <0.06).
The proportion of patients originating from the former Soviet
Union and Africa increased during the time period, whereas the
proportion of patients from southern Europe decreased. Esti-
mated survival and complication-free survival during 12 years
were 72% and 45%, respectively in cirrhotic patients compared
with 100% in non-cirrhotic patients (p <0.008 and p <0.0001,
respectively) [62].
In an Italian study of HBsAg-positive patients, 4.2% and 17% of
Italian patients and patients from outside of the EU, respectively,
had anti-HDV antibodies [63]. In north western and southern602 Journal of Hepatology 201Italy the prevalence of HDV infection was reported to be 5.7%
and 9.7%, respectively [64,65].
The prevalence of anti-HDV antibodies was 7.1% in adult UK
patients with concomitant HBV-infection, most of whom were
born in regions where HDV is endemic, e.g. southern or eastern
Europe (28.1%), Africa (26.8%) or the Middle-East (7.3%) [66].
Hepatitis E
The Hepatitis E virus (HEV) causes an acute form of hepatitis,
although infection in immunocompromised patients can result3 vol. 58 j 593–608
Table 10. European studies assessing the prevalence and incidence of autoimmune hepatitis.
Country Author, [Ref.] Study year(s) and population Incidence per 100,000 
person-years
Prevalence per 100,000 inhabitants
Norway Boberg et al., 
[147]
1986-1995; Aker University Hospital 
registry
1.9 16.9 
Spain Primo et al., 
[148]
2003; Valencia hospitals’ registries 1.07
Sweden Werner et al., 
[149]
The Swedish Internal Medicine Liver 
Club registry
0.85 10.7 
(See above-mentioned references for further information.)
Table 11. Inter-country comparison of the number of deaths associated with selected diseases compared to liver diseases based on death certiﬁcates (age-
standardized); WHO, 2008.
Population 
(millions)
Colon and 
rectum 
cancers
Breast cancer Chronic 
obstructive 
pulmonary 
disease
Nephritis and 
nephrosis
Liver cancer Cirrhosis of 
the liver
Austria 8.3 2488 1642 2425 913 782 1393
Belgium 10.6 3237 2449 4635 1294 671 1130
Bulgaria 7.6 2719 1428 1676 1351 825 1794
Czech Republic 10.3 4317 1862 2082 1059 792 2043
Denmark 5.5 2355 1439 3037 543 314 889
Estonia 1.3 426 246 222 109 90 373
Finland 5.3 1120 859 1045 285 397 1236
France 62.0 20,552 13,950 8325 7227 8024 8014
Germany 82.3 30,992 19,711 24,130 11,789 6895 15,683
Greece 11.1 2568 2196 2089 1964 1605 813
Hungary 10.0 4940 2222 4377 565 758 4870
Ireland 4.4 1039 806 1248 392 199 287
Italy 59.6 20,269 13,222 21,527 8744 9753 8165
Latvia 2.3 731 478 271 259 129 465
Lithuania 3.3 976 629 805 234 155 1379
Luxembourg 0.5 134 82 113 36 35 73
Netherlands 16.5 5423 3764 6359 1605 647 852
Norway 4.8 1762 710 2033 581 170 215
Poland 38.1 12,441 6408 8261 4944 2137 8008
Portugal 10.7 4278 1896 2690 2191 893 1537
Romania 21.4 5359 3225 5392 2200 2653 10,226
Slovakia 5.4 1960 823 675 650 379 1513
Slovenia 2.0 788 462 399 150 191 629
Spain 44.5 15,343 6711 13,843 7085 4580 4694
Sweden 9.2 2937 1694 2649 794 604 650
United Kingdom 61.2 18,951 14,343 29,069 4804 3470 7767
Total 498.3 168,107 103,255 149,377 61,767 47,147 84,697
JOURNAL OF HEPATOLOGYin chronic disease. HEV is also known to cause infections in ani-
mals, particularly pigs. Although hepatitis E has been reported
from many European countries [67] its incidence and the sero-
prevalence of the HEV infection is largely unknown in this region.Journal of Hepatology 201In studies of the Madrid general population, Catalonian chil-
dren and the Catalonian general population the prevalence of
HEV infection was reported as 2.17%, 4.6%, and 7.3%, respectively
[68–70].3 vol. 58 j 593–608 603
Special Review
In two Swiss studies the prevalence of anti-HEV antibodies in
HIV patients was 2.6% [71], while anti-HEV antibodies were
found in 4.9% of blood donor samples [72].
Among rural and urban French blood donors, Parisian blood
donors and HIV patients in Marseille the prevalence of anti-
HEV antibodies was 16.6%, 3.2%, and 4.4%, respectively [73–75].
In the Italian cities of Rome and Rieti, the prevalence of anti-
HEV antibodies among pig breeders and the general population
was 3.3% and 2.9%, respectively [76]. The prevalence in subjects
recruited in Rome and Rieti was 2.5% and 5.5%, respectively
(p = 0.0004) [76].
Non-alcoholic fatty liver disease (NAFLD)
NAFLD is deﬁned as the accumulation of liver fat exceeding 5% of
hepatocytes in the absence of signiﬁcant alcohol intake (20 g per
day for men and 10 g per day for women), viral infection, or any
other speciﬁc aetiology of liver disease. More than 50% of adults
in the EU27 are overweight or obese, both of which are important
risk factors for NAFLD. Therefore, NAFLD can be considered to be
endemic in Europe and a major potential threat to public health.
In the Barcelona and DIONYSOS studies, the prevalence of
NAFLD was 26%. In the SHIP study it was 30.4% and in the RISC
study 33% of patients had a high probability of having the disease
[77–79].
A Romanian study estimated NAFLD prevalence to be 20%
[80]. A Greek study revealed evidence of NAFLD and of non-alco-
holic steatohepatitis (NASH) in 31% and 40%, respectively, of
autopsied cases of ischaemic heart disease or trafﬁc accident
death (after exclusion of hepatitis B seropositivity or known liver
disease) [81]. A high prevalence (36–44%) of NAFLD was found in
obese children, regardless of the manner used to diagnose the
disease [82–84]. NAFLD is known to be particularly prevalent in
patients with diabetes. Two major European studies [85,86]
reported NAFLD prevalence rates of 42.6–69.5% in large samples
of type 2 diabetic patients (Table 9).
The presence of NAFLD carries an increased risk of overall
mortality and of mortality related to cardiovascular disease
(CVD) and liver disease. In a Danish study, after adjustment for
sex, diabetes and cirrhosis at baseline, NAFLD-associated age-
adjusted standardized mortality ratios (SMR) were 2.3 (95% CI
2.1–2.6) for all causes, 19.7 (95% CI 15.3–25.0) for hepatobiliary
disease, and 2.1 (95% CI 1.8–2.5) for CVD [87]. In the SHIP study
the odds ratios of all-cause mortality and CV mortality for male
patients with ultrasonographic steatosis and highest GGT quintile
were 1.98 (95% CI 1.21–3.27) and 2.41 (95% CI 1.05–5.55), respec-
tively [79]. The risk was not increased in women [79]. In a Swed-
ish study the age, sex, and calendar-period adjusted mortality
ratio was 1.69 (95% CI 1.24–2.25) for NAFLD compared to the
general population, even after excluding cirrhotic patients at
the baseline. CVD, malignancy, and liver disease were the top
three causes of death [88]. In the Italian Cremona study that fol-
lowed >2000 middle-aged individuals for 15 years the fatty liver
index was signiﬁcantly associated with a higher liver-related
mortality in a multi-adjusted analysis [89].
NAFLD already represents an important economic burden for
European countries. A German study based on the SHIP
cohort showed that subjects with sonographic fatty liver
disease and increased serum alanine amino transferase (ALT)
levels had 26% higher overall health-care costs at 5-year fol-
low-up [90].604 Journal of Hepatology 201Drug induced liver injuries (DILI)
A large proportion of drug hepatotoxicity occurs as an idiosyn-
cratic event, so that its prevalence and incidence is still only par-
tially known despite recent improvements [91,92]. A notable
exception is accidental or suicidal paracetamol intoxication,
which shows a dose-related liver toxicity, particularly when in
combination with alcohol. The majority of data are provided by
retrospective studies of databases from pharmacovigilance cen-
tres and/or pharmaceutical companies. In an analysis of a Swed-
ish database, DILI, with at least a possible causal relationship, was
found in 6.6% (77 cases) of 1664 cases. 3.3% (38 cases) were
referred for evaluation to the out-patient clinic whereas 3% had
a follow-up after hospitalization for DILI [93].
The incidence of DILI in the UK general population has been
estimated at 2.4 cases per 100,000 person years [94]. In an area
of France the incidence has been estimated at 14 cases per
100,000 persons, corresponding to a number of events 16 times
higher than that collected by pharmacovigilance centres [95].
Retrospective studies suggest that drugs may have caused
around 10–20% of all cases of fulminant and subfulminant
hepatitis [96,97]. In a French study, 5.5% of LTs were related to
drug-induced acute liver failure, of which 36.4% were due to par-
acetamol (acetaminophen) intake [98]. Of the 674 DILI references
new to the HEPATOX database between September 2010 and
August 2011, 16% concerned neuropsychiatric compounds,
including carbamazepine, phenytoin, and valproic acid. These
data are consistent with data collected in the Vigibase™ [99].
Haemochromatosis
The non-speciﬁc symptoms of this hereditary condition may be
attributed to other causes; therefore, diagnosis is often delayed.
In England and Wales during 1989/1990–2002/2003, the hos-
pital admission rate attributable to haemochromatosis among
men rose from 0.64 to 2.36 per 100,000. In women, the rate rose
from 0.21 to 0.81 per 100,000. Among men and women the age-
standardized, day case admission rate rose from 2.78 to 34.9 and
from 0.58 to 11.67 per 100,000, respectively [100].
The causative mutations in the HFE gene can be used to assess
prevalence. In Norway, the prevalence of the homozygous C282Y
mutation ranged from 0.05–0.22%. [101]. In a Romanian popula-
tion the allelic frequency of the most prevalent mutant alleles
was 1.75% (95% CI 0.7–3.7) for C282Y and 13.25% (95% CI 10.4–
16.5) for H63D [102].
In a south French registry the total prevalence of homozygous
individuals was estimated at 1.83 per 10,000 (95% CI 1.63–2.02)
in subjects >20 years old and 2.40 per 10,000 (95% CI 2.15–
2.65) among subjects of European descent. Among Europeans,
the total calculated penetrances were 15.8% for those in stage 2
haemochromatosis or higher, 12.1% for those in stage 3 or 4,
and 2.9% for those in stage 4 [103].
The allelic prevalence of the most frequent HFE gene variants
(C282Y allele, H63D and S65C) in ethnic Danish men was 5.6%,
12.8%, and 1.8%, respectively [104].
Autoimmune hepatitis (AIH)
There is no single speciﬁc test for diagnosing AIH. Consequently,
diagnosis relies on a combination of indicative features of AIH
and on the exclusion of other causes of chronic liver diseases.3 vol. 58 j 593–608
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Based on limited epidemiological data, the prevalence of AIH
is estimated to range from 50–200 cases per million among the
Caucasian population in western Europe and North America
[105].
Three recent population-based studies in Europe have esti-
mated incidence and prevalence of AIH (Table 10). AIH is com-
monly associated with liver cirrhosis but not with HCC. 32% of
278 German patients with AIH were diagnosed with liver cirrho-
sis, but none of the cohort developed HCC (average follow-up
4.8 years). This study should be interpreted with caution because
of its lack of power, but the incidence of HCC associated with
AIH-induced cirrhosis could be signiﬁcantly lower than that asso-
ciated with other causes of liver cirrhosis, such as chronic viral
hepatitis, alcohol or haemochromatosis [106].
Primary biliary cirrhosis (PBC)
Epidemiological PBC data have generally been obtained passively
and so might not indicate true rates in the general population.
Indeed, the rarity of PBC precludes a population-based approach
for the detection of cases. Differences in incidence and prevalence
of PBC are probably secondary to variation in diagnostic criteria,
case-ﬁnding methods, doctors’ awareness, and quality of health-
care systems.
Some researchers suggest that the incidence of PBC is grow-
ing. In the UK, incidence rates rose from 5.8 to 20.5 cases per mil-
lion population per year in Shefﬁeld between 1980 and 1999
[107] and from 11 to 32 cases per million population per year
in Newcastle-upon-Tyne between 1976 and 1994 [108,109]. This
increase was paralleled by a rise in prevalence to more than 200
cases per million in the mid-to-late 1990s. In Finland, the age-
standardized prevalence of PBC increased between 1988 and
1999 from 103 (95% CI 97–110) to 180 (95% CI 172–189) per mil-
lion inhabitants. Over the same period, incidence increased from
12 (95% CI 10–14) to 17 (95% CI 15–20) per million inhabitants
per year. The annual average increases in prevalence and inci-
dence were 5.1% (95% CI 4.2–5.9%, p <0.0001) and 3.5% (95% CI
0.9–6.0%, p = 0.008), respectively [110].
The progression of PBC in patients is extremely variable and
survival may be reduced when compared with an age- and gen-
der-matched population. In a Canadian study of patients whose
test results were compatible with PBC the standardized mortality
ratio was 2.87 (95% CI 1.38–4.63) [111].
Primary sclerosing cholangitis (PSC)
PSC is a chronic cholestatic liver disease of unknown aetiology. It
is particularly prevalent in the Nordic population. In a Swedish
study an incidence of 1.22 (95% CI 1.06–1.40) per 100,000 per-
son-years was observed between 1992 and 2005 [112]. A UK
study revealed an incidence of 0.91 (95% CI 0.68–1.21) per
100,000 person-years between 1984 and 2003 [113]. A study
based on the General Practice Research Database (GPRD),
reported an incidence of 0.41 (95% CI 0.34–0.48) between 1991
and 2001 [114]. In this study, and compared to the general pop-
ulation, the risk of death or liver transplantation was more than
tripled for PSC patients and the risk of all malignancy was more
than doubled. Data from this last study must be interpreted with
caution because the GPRD is not population-based and the code
for PSC was not validated.Journal of Hepatology 201It should also be noted that PSC is one of the principal aetiol-
ogies of LT in cases of cholestatic disease.Conclusion
The data reviewed here clearly demonstrate the signiﬁcant bur-
den of liver disease in Europe. Liver disease associated mortality
in this region is at least comparable with other diseases that are
considered to be of major public health concern (Table 11). Dis-
eases such as breast cancer are high on the public health agenda
with dedicated screening programmes; therefore healthcare pro-
viders and governments must mobilise resources to see that liver
disease is tackled in a similarly proactive fashion. This review in
conjunction with further surveys of the liver disease burden in
Europe will hopefully be the impetus for the design and imple-
mentation of strategies that will ameliorate this problem and
ultimately save lives.Conﬂict of interest
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